Personalized preventive medicine and neurology


DOI: https://dx.doi.org/10.18565/therapy.2018.7-8.20-24

A.A. Pilipovich, Al.B. Danilov

The Department of nervous diseases of I.M. Sechenov First Moscow State Medical University FSAEI of HE of the Ministry of Healthcare of Russia (Sechenov University)
The progression of many prevalent non-infectious diseases is associated with a complex interaction of many factors (including environmental factors and the internal body factors) at various levels, including genetic one. In neurology, this deals with all neurodegenerative diseases, the etiology and pathogenesis of which remain not fully understood - Alzheimer’s, Parkinson’s and other degenerative pathology. Moreover, that is true for cerebrovascular, demyelinating and other non-infectious diseases of the nervous system. In «gene-environment» studies, the focus is put on risk factors identification that cannot be detected using conventional epidemiological methods, as a rule, excluding accurate prognostications. Specific risk factors can only be identified after a detailed analysis of the interactions between all the components. For the moment, promising results have been obtained in a number of cohort studies, but they are not still enough to develop accurate personalized preventive medicine. Large-scale long-term studies are required to find useful practical provement for the development of preventive medicine.
Keywords: preventive neurology, personalized preventive medicine, preclinical diagnostics, preventive medicine, gene-environment studies
Read entire article

Literature

  • Hiroto Narimatsu. Gene–Environment Interactions in Preventive Medicine: Current Status and Expectations for the Future. Int. J. Mol. Sci. 2017; 18(2): 302.
  • Khachaturian Z.S., Camí J., Andrieu S., Avila J., Boada Rovira M., Breteler M., Froelich L., Gauthier S., Gómez-Isla T., Khachaturian A.S., Kuller L.H., Larson E.B., Lopez O.L., Martinez-Lage J.M., Petersen R.C., Schellenberg G.D., Sunyer J., Vellas B., Bain L.J. Creating a transatlantic research enterprise for preventing Alzheimer’s disease. Alzh. Dement. 2009; 5(4): 361–6.
  • Khachaturian Z.S., Petersen R.C., Snyder P.J., Khachaturian A.S., Aisen P., de Leon M., Greenberg B.D., Kukull W., Maruff P., Sperling R.A., Stern Y., Touchon J., Vellas B., Andrieu S., Weiner M.W., Carrillo M.C., Bain L.J. Developing a global strategy to prevent Alzheimer’s disease: Leon Thal Symposium 2010. Alzh. Dement. 2011; 7(2): 127–32.
  • Solomon A., Mangialasche F., Richard E., Andrieu S., Bennett D.A., Breteler M., Fratiglioni L., Hooshmand B., Khachaturian A.S., Schneider L.S., Skoog I., Kivipelto M. Advances in the prevention of Alzheimer’s disease and dementia. J. Int. Med. 2014; 275(3): 229–50.
  • Manolio T.A., Bailey-Wilson J.E., Collins F.S. Genes, environment and the value of prospective cohort studies. Nat. Rev. Genet. 2006; 7(10): 812–20.
  • Manolio T.A. Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 2010; 363(2): 166–76.
  • Hamajima N., J-MICC Study Group. The Japan Multi-Institutional Collaborative Cohort Study (J-MICC Study) to detect gene-environment interactions for cancer. Asian. Pac. J. Cancer Prev. 2007; 8(2): 317–23.
  • Keyes K.M., Utz R.L., Robinson W., Li G. What is a cohort effect? Comparison of three statistical methods for modeling cohort effects in obesity prevalence in the United States, 1971–2006. Soc. Sci. Med. 2010; 70(7): 1100–8.
  • Yamagata University Genomic Cohort Consortium. Narimatsu H. Constructing a contemporary gene-environmental cohort: study design of the Yamagata Molecular Epidemiological Cohort Study. J. Hum. Genet. 2013; 58(1): 54–6.
  • Gauderman W.J. Sample size requirements for matched case-control studies of gene-environment interaction. Stat. Med. 2002; 21(1): 35–50.
  • UK Biobank Home Page. Available online: http://www.ukbiobank.ac.uk/ [Ref. list].
  • Holmes M.V., Dale C.E., Zuccolo L., Silverwood R.J. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ. 2014; 349: g4164.
  • Manolio T.A., Collins F.S., Cox N.J., Goldstein D.B., Hindorff L.A., Hunter D.J., McCarthy M.I., Ramos E.M., Cardon L.R., Chakravarti A. et al. Finding the missing heritability of complex diseases. Nature.2009; 461: 747–53.
  • McCarthy M.I., Abecasis G.R., Cardon L.R., Goldstein D.B., Little J., Ioannidis J.P., Hirschhorn J.N. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat. Rev. Genet. 2008; 9(5): 356–69.
  • Ueki M., Tamiya G. Ultrahigh-dimensional variable selection method for whole-genome gene-gene interaction analysis. BMC Bioinformatics. 2012; 13: 72.


    • About the Autors

    Anna A. Pilipovich, PhD, associate professor of the Department of nervous diseases of the Institute of Professional Education of «I.M. Sechenov First Moscow State Medical University» FSAEI of HE of the Ministry of Healthcare of Russia (Sechenov University). Address: 119991, Moscow, 2, bld. 4, Bolshaya Pirogovskaya St. Tel. +784956091400. E-mail: aapilipovich@mail.ru
    Alexey B. Danilov, MD, professor, head of the Department of nervous diseases the Institute of Professional Education of «I.M. Sechenov First Moscow State Medical University» FSAEI of HE of the Ministry of Healthcare of Russia (Sechenov University) Address: 119991, Moscow, 2, bld. 4, Bolshaya Pirogovskaya St. Tel. +7 (495) 609-14-00. E-mail: nervkafedra@gmail.com

    Back to Content

    Бионика Медиа